Kyowa Kirin Receives Positive CHMP Opinion for the Expanded Use of CRYSVITA® (burosumab) to Include Older Adolescents and Adults for the Treatment of X-Linked Hypophosphataemia (XLH)
XLH is a rare, life-long genetic disease that causes abnormalities in the bones, muscles and joints1,2,3 TOKYO–(BUSINESS WIRE)– Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin)...